Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18955967 | DRUGS FOR PREVENTION OR TREATMENT OF SEPSIS | November 2024 | January 2025 | Allow | 2 | 0 | 0 | No | No |
| 18864911 | SIRNA SPECIFICALLY BINDING TO M2 MACROPHAGE CD206 AND APPLICATION THEREOF | November 2024 | June 2025 | Allow | 7 | 1 | 0 | No | No |
| 18930307 | METHOD FOR PREVENTING DSRNA BACTERIAL SOLUTIONS FROM BEING DEGRADED BY UVLIGHT AND APPLICATION THEREOF IN CONTROL OF SILVERLEAF WHITEFLIES | October 2024 | March 2025 | Allow | 4 | 1 | 0 | No | No |
| 18801051 | SYNTHETIC SELF-AMPLIFYING MRNA MOLECULES WITH SECRETION ANTIGEN AND IMMUNOMODULATOR | August 2024 | May 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18793716 | APPLICATION OF MECHANICAL-FORCE SENSITIVE MACROPHAGE SUBSET IN PANCREATIC CANCER DIAGNOSIS OR PROGNOSIS EVALUATION | August 2024 | June 2025 | Allow | 10 | 2 | 0 | No | No |
| 18751048 | ADVANCED RNA TARGETING (ARNATAR) FOR ANGIOTENSINOGEN | June 2024 | December 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18660600 | COMPOUNDS TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE | May 2024 | April 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18654906 | REAGENTS AND METHODS USED IN DEPROTECTION OF 3'-O-AMINO POLYNUCLEOTIDES | May 2024 | October 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18427866 | SIGNAL BOOST CASCADE ASSAY | January 2024 | July 2024 | Allow | 5 | 3 | 0 | No | No |
| 18387017 | cGMP EXOSOME LOADED THERAPEUTICS FOR TREATING SICKLE CELL DISEASE | November 2023 | January 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18467224 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | September 2023 | November 2024 | Allow | 14 | 3 | 1 | Yes | No |
| 18467190 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | September 2023 | April 2024 | Allow | 7 | 1 | 0 | No | No |
| 18234402 | SIGNAL BOOST CASCADE ASSAY | August 2023 | January 2024 | Allow | 5 | 1 | 1 | No | No |
| 18260789 | USE OF GANODERMA FUNGAL RNA MOLECULES, DRUG, DRUG COMPOSITION AND DELIVERY CARRIER | July 2023 | May 2025 | Allow | 22 | 2 | 0 | No | No |
| 18327434 | RECONFIGURABLE DNA NANO-TWEEZER | June 2023 | March 2025 | Allow | 22 | 1 | 0 | No | No |
| 18169779 | VARIANT RNAi | February 2023 | February 2025 | Allow | 24 | 0 | 0 | No | No |
| 18159465 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | January 2023 | May 2025 | Allow | 28 | 2 | 0 | No | No |
| 18148396 | MODIFICATIONS OF MAMMALIAN CELLS USING ARTIFICIAL MICRO-RNA TO ALTER THEIR PROPERTIES AND THE COMPOSITIONS OF THEIR PRODUCTS | December 2022 | March 2025 | Allow | 26 | 2 | 1 | No | No |
| 18057809 | METHODS AND COMPOSITIONS FOR STUDYING CELL EVOLUTION | November 2022 | May 2025 | Allow | 30 | 1 | 1 | No | No |
| 17989526 | NOVEL POLYINOSINIC - POLYCYTIDYLIC ACID COMPOSITIONS AND METHODS OF MAKING SAME | November 2022 | May 2025 | Allow | 30 | 3 | 0 | No | No |
| 17988625 | NOVEL POLYINOSINIC - POLYCYTIDYLIC ACID COMPOSITIONS | November 2022 | April 2025 | Allow | 29 | 1 | 0 | No | No |
| 17949048 | USE OF P38 INHIBITORS TO REDUCE EXPRESSION OF DUX4 | September 2022 | March 2025 | Abandon | 30 | 0 | 1 | No | No |
| 17898292 | RIG-I Agonists and Methods of Using Same | August 2022 | June 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17818656 | DE NOVO SYNTHESIZED GENE LIBRARIES | August 2022 | June 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17881471 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | August 2022 | June 2025 | Allow | 34 | 2 | 0 | No | No |
| 17816696 | RNA POLYMERASE VARIANTS FOR CO-TRANSCRIPTIONAL CAPPING | August 2022 | July 2024 | Allow | 23 | 0 | 0 | No | No |
| 17864129 | Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms | July 2022 | February 2025 | Abandon | 31 | 0 | 1 | No | No |
| 17826252 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | May 2022 | April 2025 | Allow | 35 | 1 | 1 | No | No |
| 17752530 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING OLIGONUCLEOTIDE BASED DRUGS ADMINISTERED IN VIVO OR IN VITRO | May 2022 | January 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 17734460 | PARTICLES AND COMPOSITIONS COMPRISING THE SAME FOR TRANSFECTION | May 2022 | December 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17773545 | THERAPEUTIC DOUBLE STRANDED RNA AND METHODS FOR PRODUCING THE SAME | April 2022 | April 2025 | Allow | 36 | 4 | 1 | No | Yes |
| 17731259 | METHOD OF STIMULATING PROLIFERATION OF A CELL | April 2022 | May 2025 | Allow | 37 | 1 | 1 | Yes | No |
| 17658075 | IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | April 2022 | January 2025 | Allow | 33 | 1 | 1 | No | No |
| 17677875 | MODULATORS OF DIACYGLYCEROL ACYLTRANSFERASE 2 (DGAT2) | February 2022 | September 2024 | Allow | 31 | 0 | 1 | No | No |
| 17558705 | METHODS FOR DIAGNOSING AND TREATING METASTATIC CANCER | December 2021 | May 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17538217 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | November 2021 | February 2025 | Allow | 38 | 1 | 1 | No | No |
| 17535191 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | November 2021 | March 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17612120 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL | November 2021 | December 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17528828 | COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES | November 2021 | September 2024 | Allow | 34 | 1 | 1 | No | No |
| 17523060 | HIGH PURITY RNA COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | November 2021 | September 2024 | Allow | 35 | 1 | 0 | No | No |
| 17523034 | HIGH PURITY RNA COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | November 2021 | October 2024 | Allow | 36 | 1 | 0 | No | No |
| 17512280 | METHOD AND COMPOSITION FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | October 2021 | November 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17509648 | METHODS OF MEASURING C19MC miRNA IN A POST-NATAL TISSUE AND USES THEREOF | October 2021 | February 2025 | Allow | 39 | 2 | 1 | No | No |
| 17448996 | Composition and Methods for Treatment of Ornithine Transcarbamylase Deficiency | September 2021 | December 2024 | Allow | 38 | 1 | 1 | No | No |
| 17405482 | MicroRNA Compounds and Methods for Modulating MIR-21 Activity | August 2021 | February 2025 | Allow | 42 | 2 | 1 | No | No |
| 17398490 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | August 2021 | December 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17375658 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | July 2021 | February 2025 | Allow | 43 | 1 | 1 | No | No |
| 17420195 | METHOD AND APPARATUS FOR INVESTIGATING INTRA- AND/OR INTERMOLECULAR INTERACTIONS INVOLVING RNA | July 2021 | December 2024 | Allow | 41 | 0 | 1 | No | No |
| 17354818 | METHODS AND COMPOSITIONS FOR TREATING HEMOPHILIA | June 2021 | December 2024 | Allow | 41 | 4 | 1 | Yes | No |
| 17335499 | CLOSED-ENDED LINEAR DUPLEX DNA FOR NON-VIRAL GENE TRANSFER | June 2021 | November 2024 | Allow | 41 | 1 | 1 | No | No |
| 17332249 | CHIMERIC DOUBLE-STRANDED NUCLEIC ACID | May 2021 | April 2025 | Allow | 47 | 3 | 1 | No | No |
| 17292710 | COMPOSITION COMPRISING APTAMER AS ACTIVE INGREDIENT FOR TREATMENT AND PREVENTION OF DEGENERATIVE BRAIN DISEASE | May 2021 | October 2024 | Allow | 41 | 1 | 0 | No | No |
| 17292292 | MINI-NUCLEOSOME CORE PROTEINS AND USE IN NUCLEIC ACID DELIVERY | May 2021 | June 2025 | Allow | 49 | 4 | 1 | No | No |
| 17308888 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | May 2021 | September 2024 | Allow | 41 | 3 | 1 | Yes | No |
| 17237856 | Compositions of Asymmetric Interfering RNA and Uses Thereof | April 2021 | March 2025 | Allow | 46 | 2 | 1 | No | No |
| 17221867 | SHORT INTERFERING RNA TEMPLATED LIPOPROTEIN PARTICLES (SIRNA-TLP) | April 2021 | October 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17279574 | METHODS FOR MONITORING RESPONSE TO TREATMENT | March 2021 | January 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17276898 | SUBSTRATE FOR NUCLEIC ACID ANALYSIS, FLOW CELL FOR NUCLEIC ACID ANALYSIS, AND IMAGE ANALYSIS METHOD | March 2021 | October 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17194706 | Methods of Treating Porphyria | March 2021 | August 2024 | Allow | 41 | 2 | 1 | No | No |
| 17194821 | MUTANT CSGG PORES | March 2021 | November 2024 | Allow | 45 | 1 | 1 | No | No |
| 17193999 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF | March 2021 | January 2025 | Allow | 47 | 1 | 1 | No | No |
| 17191222 | COMPOSITIONS FOR SELECTION OF APTAMERS | March 2021 | February 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17187669 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | February 2021 | October 2024 | Allow | 43 | 3 | 1 | Yes | No |
| 17144365 | Silencing of HNF4A-P2 Isoforms with siRNA to Improve Hepatocyte Function in Liver Failure | January 2021 | August 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 17258880 | METHODS FOR QUANTITATION OF ANALYTES IN MULTIPLEXED BIOCHEMICAL REACTIONS | January 2021 | March 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17130908 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EXPANDED REPEAT-ASSOCIATED DISORDERS | December 2020 | August 2024 | Allow | 44 | 2 | 1 | No | Yes |
| 17251921 | RIG-I Agonists and Treatments Using Same | December 2020 | February 2025 | Allow | 50 | 2 | 1 | No | No |
| 17117025 | C/EBP ALPHA SARNA COMPOSITIONS AND METHODS OF USE | December 2020 | May 2025 | Abandon | 53 | 2 | 1 | No | Yes |
| 17058817 | Methods for the Treatment of Bladder Cancer | November 2020 | July 2024 | Allow | 44 | 2 | 0 | Yes | No |
| 17047011 | THERAPEUTIC CONSTRUCTS FOR TREATING CANCER | October 2020 | October 2024 | Allow | 48 | 1 | 1 | No | No |
| 17026473 | METHOD OF SYNTHESIS OF AN IONIZABLE CATIONIC LIPID | September 2020 | December 2024 | Allow | 51 | 2 | 0 | No | No |
| 17016313 | CHIRAL DESIGN | September 2020 | February 2023 | Allow | 29 | 2 | 0 | No | No |
| 16967926 | PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS | August 2020 | November 2024 | Abandon | 51 | 1 | 1 | No | No |
| 16966430 | POLYNUCLEOTIDE SYNTHESIS METHOD, KIT AND SYSTEM | July 2020 | August 2024 | Allow | 49 | 2 | 1 | Yes | No |
| 16927346 | METHODS AND MATERIALS FOR DISCOVERY OF FUNCTIONAL LIGANDS TO MOLECULAR COMPLEXES | July 2020 | February 2025 | Allow | 55 | 1 | 1 | No | No |
| 16147844 | NOVEL RNA CONSTRUCT AND METHODS OF USE THEREOF FOR ENHANCING THE THERAPEUTIC EFFECTS OF CYTOTOXIC CELLS AND STEM CELLS | September 2018 | September 2021 | Abandon | 36 | 2 | 1 | No | No |
| 15779633 | THERAPEUTIC TARGETS FOR THE CORRECTION OF THE HUMAN DYSTROPHIN GENE BY GENE EDITING AND METHODS OF USE | May 2018 | September 2023 | Allow | 60 | 6 | 1 | Yes | No |
| 15990542 | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF-LIFE AND USES THEREOF | May 2018 | January 2019 | Allow | 8 | 1 | 0 | No | No |
| 15536006 | SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR INHIBITING TGF-BETA1 EXPRESSION | June 2017 | April 2019 | Allow | 22 | 2 | 0 | No | No |
| 15513861 | Method for Assessing the Efficacy of IMIDS and Composition or Combination for Use in Treating IMID Sensitive Diseases | March 2017 | April 2019 | Allow | 25 | 1 | 1 | No | No |
| 15508424 | OLIGONUCLEOTIDE TARGETED TO THE A20-THREE PRIME UNTRANSLATED REGION | March 2017 | May 2020 | Allow | 38 | 4 | 1 | No | No |
| 15367947 | MIR-193A-3P AND ASSOCIATED GENES PREDICT TUMORIGENESIS AND CHEMOTHERAPY OUTCOMES | December 2016 | August 2018 | Allow | 20 | 1 | 0 | No | No |
| 15199139 | MICRO-RNA INHIBITOR | June 2016 | November 2018 | Allow | 28 | 2 | 1 | No | No |
| 15012052 | COMPOSITIONS, KITS AND METHODS FOR TREATMENT OF CARDIOVASCULAR,IMMUNOLOGICAL AND INFLAMMATORY DISEASES | February 2016 | July 2018 | Allow | 29 | 2 | 0 | No | No |
| 15010837 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING OLIGONUCLEOTIDE BASED DRUGS ADMINISTERED IN VIVO OR IN VITRO | January 2016 | February 2019 | Allow | 37 | 2 | 1 | No | No |
| 14922954 | TREATMENT OF SEX HORMONE BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SHBG | October 2015 | February 2020 | Allow | 52 | 7 | 1 | No | No |
| 13653013 | COMPOSITIONS AND METHODS FOR SHORT INTERFERING NUCLEIC ACID INHIBITION OF NAV1.8 | October 2012 | January 2014 | Allow | 15 | 0 | 1 | No | No |
| 13469402 | TREATMENT OF CANCER BY INHIBITION OF IGFBPS AND CLUSTERIN | May 2012 | May 2013 | Allow | 12 | 4 | 0 | No | No |
| 13466631 | SIRNA TARGETING CATENIN, BETA-1 (CTNNB1) | May 2012 | November 2012 | Allow | 7 | 0 | 1 | No | No |
| 13386154 | POLYION COMPLEX COMPRISING PHD2 EXPRESSION INHIBITING SUBSTANCE | March 2012 | January 2014 | Allow | 24 | 2 | 2 | No | No |
| 13344303 | MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF JOINT DEGENERATIVE AND INFLAMMATORY DISEASES | January 2012 | November 2013 | Allow | 22 | 2 | 1 | No | No |
| 13138224 | PHD2 INHIBITION FOR BLOOD VESSEL NORMALIZATION, AND USES THEREOF | October 2011 | December 2013 | Allow | 29 | 2 | 1 | No | No |
| 13246696 | USE OF A GROWTH-STIMULATING PROTEIN | September 2011 | November 2012 | Allow | 14 | 1 | 1 | No | No |
| 13087618 | TREATMENT OF CANCER BY INHIBITION OF IGFBPS AND CLUSTERIN | April 2011 | May 2012 | Allow | 13 | 2 | 0 | No | No |
| 13087627 | Treatment of Cancer by Inhibition of IGFBPs and Clusterin | April 2011 | March 2013 | Allow | 23 | 3 | 0 | No | Yes |
| 13079525 | POTENT LNA OLIGONUCLEOTIDES FOR THE INHIBITION OF HIF-1A EXPRESSION | April 2011 | November 2012 | Allow | 20 | 1 | 0 | No | No |
| 13072915 | Method of Selectively Inhibiting the Activity of ACAT1 in the Treatment of Alzheimer's Disease | March 2011 | February 2013 | Allow | 23 | 1 | 1 | No | No |
| 12789564 | COMPOSITIONS AND METHODS FOR SHORT INTERFERING NUCLEIC ACID INHIBITION OF NAV1.8 | May 2010 | July 2012 | Allow | 25 | 1 | 1 | No | No |
| 12600803 | MICRO-RNAS MODULATING IMMUNITY AND INFLAMMATION | May 2010 | December 2012 | Allow | 37 | 1 | 1 | No | No |
| 12597458 | MODULATION OF BLOOD BRAIN BARRIER PROTEIN EXPRESSION | April 2010 | December 2012 | Allow | 38 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ZARA, JANE J.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ZARA, JANE J works in Art Unit 1637 and has examined 202 patent applications in our dataset. With an allowance rate of 91.6%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner ZARA, JANE J's allowance rate of 91.6% places them in the 76% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by ZARA, JANE J receive 1.92 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by ZARA, JANE J is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +9.9% benefit to allowance rate for applications examined by ZARA, JANE J. This interview benefit is in the 46% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 37.0% of applications are subsequently allowed. This success rate is in the 81% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 72.4% of cases where such amendments are filed. This entry rate is in the 92% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 92.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 53.7% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 24.8% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.7% of allowed cases (in the 87% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.